Silja Schrader

Silja Schrader

Auto-generated profile, based on publicly available information

Silja Schrader

Department of General Practice, Medicine, Dentristry and Health Services, The University of Melbourne, Melbourne, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in Vaccine
Verified
Journal Article
Closed access
PSPriya Shenton
Priya Shenton
SSSilja Schrader
Silja Schrader
JSJulia Smith
Julia Smith
AAAnnette Alafaci
Annette Alafaci
NCNicholas Cox
Nicholas Cox
DCDaryl R. Cheng
Daryl R. Cheng

19 March 2023 in Expert Review of Vaccines
Verified
Journal Article
Open access
NPNikki Petrakis
Nikki Petrakis
MAMel Addison
Mel Addison
BPBianca Penak
Bianca Penak
SSSilja Schrader
Silja Schrader
JMJohn Mallard
John Mallard
DCDaryl R Cheng
Daryl R Cheng
: Shoulder Injury Related to Vaccine Administration (SIRVA) is a preventable adverse event following incorrect vaccine administration, which can result in significant long-term morbidity. There has been a notable surge in reported cases of SIRVA as a rapid national population-based COVID-19 immunization program has been rolled out across Australia. : Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC) in Victoria, identified 221 suspected cases of SIRVA following the commencement of the COVID-19 vaccination program, reported between February 2021 and February 2022. This review describes the clinical features and outcomes of SIRVA in this population. Additionally, a suggested diagnostic algorithm is proposed, in order to facilitate early recognition and management of SIRVA. : 151 cases were confirmed as SIRVA, with 49.0% having received vaccines at state vaccination centers. 75.5% were suspected incorrect administration site, with most patients experiencing shoulder pain and restricted movement within 24 hours of vaccination, lasting on average 3 months. Improved awareness and education regarding SIRVA is imperative in a pandemic vaccine roll-out. The development of a structured framework for evaluating and managing suspected SIRVA will aid in timely diagnosis and treatment, essential to mitigate potential long-term complications.

6 February 2026 in JMIR Formative Research
Verified
Journal Article
Open access
JGJaviera Martinez Gutierrez
Javiera Martinez Gutierrez
KSKaleswari Somasundaram
Kaleswari Somasundaram
CBChristina Maresch Bernardes
Christina Maresch Bernardes
MRMeena Rafiq
Meena Rafiq
SSSilja Schrader
Silja Schrader
JEJon Emery
Jon Emery
Background: Early detection in primary care could improve pancreatic cancer survival, but diagnosis is often delayed due to the low prevalence of the disease, the nonspecific nature of early symptoms, and the broad range of conditions and volume of consultations managed by general practitioners (GPs). In Australia, improving pancreatic cancer outcomes, including via earlier diagnosis, is a priority being progressed under the National Pancreatic Cancer Roadmap developed by Cancer Australia. Computerized clinical decision support systems (CDSSs) have shown promise in aiding timely cancer diagnosis; however, barriers to adopting CDSS such as mistrust of the recommendations or not being embedded in the clinical workflow remain. Simulation techniques, which offer flexible and cost-effective ways to evaluate digital health interventions, can be used to test CDSS before real-world implementation. Objective: This study aims to assess the acceptability and feasibility of identifying patients with symptoms associated with pancreatic cancer through a CDSS within a simulated environment. Methods: We developed a CDSS that interacted with an electronic health record used in general practice to identify patients with symptoms, which may indicate pancreatic cancer (unintended weight loss or new-onset diabetes), in a simulation laboratory for digital interventions. We tested it by inviting GPs (n=11) to use the CDSS, with patient actors simulating specific clinical scenarios. We then interviewed GPs about the interaction to assess the acceptability and feasibility of the CDSS in their clinical practice. We used thematic analysis and 2 relevant frameworks to analyze the data. Results: GPs found the CDSS easy to use, unobstructive, and effective as a prompt to consider investigations for people with risk factors for pancreatic cancer. However, they expressed concerns about possible overtesting, financial costs, and the potential for anxiety in patients with a very low probability of having cancer. Conclusions: While GPs found the tool useful and compatible with their workflow, concerns about overtesting, lack of evidence, and cost-effectiveness were identified as barriers. GPs favored a stepwise approach to investigations rather than immediate imaging. Despite the overall acceptability of the tool, additional evidence to underpin clinical recommendations is necessary before implementing a CDSS with these specific recommendations for pancreatic cancer in primary care.

6 January 2026 in British Journal of General Practice
Verified
Journal Article
Open access
PDF file
SSSilja Schrader
Silja Schrader
MRMeena Rafiq
Meena Rafiq
JGJaviera Martinez Gutierrez
Javiera Martinez Gutierrez
MWMary Waterhouse
Mary Waterhouse
BLBelinda Lee
Belinda Lee
JEJon Emery
Jon Emery
Background: Pancreatic cancer is often diagnosed at an advanced stage with poor survival. Risk assessment tools have been developed to aid early diagnosis of pancreatic cancer in primary care settings (QCancer ® , electronic Risk Assessment Tool [eRAT], and the Queensland Institute of Medical Research [QIMR] Berghofer Pancreatic Cancer Decision Support Tool [QPaC Tool]) but have not been validated in the Australian setting. Aim: To estimate and compare the performance of these tools for identifying patients with undiagnosed pancreatic cancer using Australian primary care data. Design and setting: A cohort study was conducted using linked primary care and cancer registry data from Victoria, Australia. Method: Patients presenting to primary care with signs and/or symptoms included in the tools (recorded in the primary care ‘reason for encounter’) were included. Diagnostic accuracy statistics for each tool (and their individual signs and symptoms) were compared. Results: Patients with pancreatic cancer were more likely ( P <0.001) to present with new-onset diabetes, jaundice, and unexpected weight loss pre-diagnosis than patients without pancreatic cancer. The most common pre-diagnostic presentations in patients with pancreatic cancer were jaundice (29.0%), abdominal pain (25.6%), change in bowel habits (17.6%), and new-onset diabetes (14.8%). Jaundice, steatorrhoea, and pancreatitis had the highest positive predictive values (PPV) for pancreatic cancer (1.96%, 1.77%, and 0.89%, respectively). Among the tools, eRAT had the highest PPV of 1.37% (95% confidence interval [CI] = 1.12 to 1.66); the PPV for QPaC was 1.01% (95% CI = 0.82 to 1.22) and QCancer ® was 0.8% (95% CI = 0.54 to 1.15). Conclusion: When applied to Australian primary care data, none of the tools were strongly predictive of pancreatic cancer. New diagnostic models incorporating additional data could potentially improve their predictive performance.

14 November 2025 in BJGP Open
Verified
Journal Article
Open access
PDF file
RNRachel Neale
Rachel Neale
SJSusan J Jordan
Susan J Jordan
BTBridie Thompson
Bridie Thompson
CBChristina Maresch Bernardes
Christina Maresch Bernardes
JAJudi Adams
Judi Adams
MWMary Waterhouse
Mary Waterhouse
Background: Pancreatic cancer causes non-specific symptoms, potentially leading to delays in diagnosis. Decision support tools may help primary care practitioners to triage patients for pancreatic imaging. Aim: To investigate the sensitivity of three different tools for identifying patients who may have pancreatic cancer. Design & setting: An observational study in Australia. Method: We investigated the performance of the Risk Assessment Tool (RAT) for pancreatic cancer, the QCancer ® tool, and a tool developed through a consensus process led by QIMR Berghofer (the QPaC Tool). We applied these tools to people with pancreatic cancer who were interviewed about their symptoms on first presentation to a clinician. We designated patients as ‘flagged’ by each tool if they met specific criteria, and calculated the percentage flagged (that is, the sensitivity). Participants with jaundice were excluded from analyses of QCancer ® . Results: We included 190 participants in analyses of the RAT and QPaC Tool (142 in analyses of QCancer ® ). The sensitivity of the QPaC Tool and the RAT were 54% and 27%, respectively. QCancer ® had a sensitivity of 14%, at a probability threshold of 1%; in the same 142 participants, QPaC and the RAT flagged 44% and 7%, respectively. Conclusion: The QPaC Tool was the most sensitive, largely owing to its inclusion of severe epigastric pain and emphasis on diabetes, but it has unknown specificity. More research is needed to determine whether any tool could reduce delays in diagnosis; in the interim, the QPaC Tool may support clinicians to consider pancreatic cancer in their differential diagnoses.

17 June 2025 in JMIR Preprints
Verified
Preprint
Open access
JGJaviera Martinez Gutierrez
Javiera Martinez Gutierrez
KSKaleswari Somasundaram
Kaleswari Somasundaram
CBChristina Maresch Bernardes
Christina Maresch Bernardes
MRMeena Rafiq
Meena Rafiq
SSSilja Schrader
Silja Schrader
JEJon Emery
Jon Emery
BACKGROUND Early detection in primary care could improve pancreatic cancer survival, but diagnosis is often delayed due to the low prevalence of the disease, the nonspecific nature of early symptoms, and the broad range of conditions and volume of consultations managed by general practitioners (GPs). In Australia, improving pancreatic cancer outcomes, including via earlier diagnosis, is a priority being progressed under the National Pancreatic Cancer Roadmap developed by Cancer Australia. Computerized clinical decision support systems (CDSSs) have shown promise in aiding timely cancer diagnosis; however, barriers to adopting CDSS such as mistrust of the recommendations or not being embedded in the clinical workflow remain. Simulation techniques, which offer flexible and cost-effective ways to evaluate digital health interventions, can be used to test CDSS before real-world implementation. OBJECTIVE This study aims to assess the acceptability and feasibility of identifying patients with symptoms associated with pancreatic cancer through a CDSS within a simulated environment. METHODS We developed a CDSS that interacted with an electronic health record used in general practice to identify patients with symptoms, which may indicate pancreatic cancer (unintended weight loss or new-onset diabetes), in a simulation laboratory for digital interventions. We tested it by inviting GPs (n=11) to use the CDSS, with patient actors simulating specific clinical scenarios. We then interviewed GPs about the interaction to assess the acceptability and feasibility of the CDSS in their clinical practice. We used thematic analysis and 2 relevant frameworks to analyze the data. RESULTS GPs found the CDSS easy to use, unobstructive, and effective as a prompt to consider investigations for people with risk factors for pancreatic cancer. However, they expressed concerns about possible overtesting, financial costs, and the potential for anxiety in patients with a very low probability of having cancer. CONCLUSIONS While GPs found the tool useful and compatible with their workflow, concerns about overtesting, lack of evidence, and cost-effectiveness were identified as barriers. GPs favored a stepwise approach to investigations rather than immediate imaging. Despite the overall acceptability of the tool, additional evidence to underpin clinical recommendations is necessary before implementing a CDSS with these specific recommendations for pancreatic cancer in primary care.